Last reviewed · How we verify
HR19042 Capsules
At a glance
| Generic name | HR19042 Capsules |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy. (PHASE2)
- Relative Bioavailability Study of HR19042 in Healthy Subjects (PHASE1)
- A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis. (PHASE2)
- A Trial of HR19042 Capsule in Healthy Chinese Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HR19042 Capsules CI brief — competitive landscape report
- HR19042 Capsules updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI